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Low uptake of continuous subcutaneous
insulin infusion therapy in people with type
1 diabetes in Ireland: a retrospective cross-
sectional study
Katarzyna Anna Gajewska1* , Kathleen Bennett1, Regien Biesma2 and Seamus Sreenan3,4
Abstract
Background: The uptake of continuous subcutaneous insulin infusion (CSII) therapy in those with type 1 diabetes
varies internationally and is mainly determined by the national healthcare reimbursement systems. The aim of this
study is to estimate national and regional uptake of CSII therapy in children, adolescents and adults with type 1
diabetes in Ireland.
Methods: A retrospective cross-sectional study was conducted utilizing the national pharmacy claims database in
2016. Individuals using CSII were identified by dispensing of infusion sets. The uptake of CSII was calculated as the
percentage of people with type 1 diabetes claiming CSII sets in 2016, both in children and adolescent (age < 18
years) and adult populations (≥ 18 years). Descriptive statistics including percentages with 95% confidence intervals
(CIs) are presented, stratified by age-groups and geographical regions, and chi-square tests used for comparisons.
Results: Of 20,081 people with type 1 diabetes, 2111 (10.5, 95% CI: 10.1–10.9%) were using CSII in 2016. Uptake was
five-fold higher in children and adolescents at 34.7% (95% CI: 32.9–36.5%) than in adults at 6.8% (95% CI: 6.4–7.2%).
Significant geographical heterogeneity in CSII uptake was found, from 12.6 to 53.7% in children and adolescents
(p < 0.001), and 2 to 9.6% in adults (p < 0.001).
Conclusions: Uptake of CSII in people with type 1 diabetes is low in Ireland, particularly in those ≥18 years.
Identification of barriers to uptake, particularly in this group, is required.
Keywords: Diabetes mellitus, type 1, Insulin infusion systems, Insulin pump, Epidemiology, Health services research,
Cross-sectional studies
Background
Continuous Subcutaneous Insulin Infusion (CSII) was
introduced as a mode of insulin administration for type
1 diabetes in the late 1970s [1]. The International Soci-
ety of Paediatric and Adolescent Diabetes (ISPAD) rec-
ommends CSII as a preferred method of insulin
administration for preschool children [2], due to its ad-
vantages: better precision and accuracy; flexibility; ease
of insulin delivery [1]. Consensus statements from the
major international diabetes associations [3] and system-
atic reviews and meta-analyses [4] suggest a lower risk
of hypoglycaemia (including severe events), as well as
modest reductions in glycated haemoglobin (HbA1c)
when comparing CSII to insulin injections in those
under 18 years of age [3, 4].
© The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License,
which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if
changes were made. The images or other third party material in this article are included in the article's Creative Commons
licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons
licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the
data made available in this article, unless otherwise stated in a credit line to the data.
* Correspondence: katarzynagajewska@rcsi.ie
1Division of Population Health Scineces, RCSI: University of Medicine and
Health Sciences, Dublin, Ireland
Full list of author information is available at the end of the article
Gajewska et al. BMC Endocrine Disorders           (2020) 20:92 
https://doi.org/10.1186/s12902-020-00573-w
The effectiveness of CSII in adult populations with
type 1 diabetes is less evident: systematic reviews and
randomized controlled trials (RCTs) of CSII effectiveness
in adults with type 1 diabetes reported advantages over
multiple daily injections (MDI) such as better control of
glucose levels, less hypoglycaemia and quality of life
gains [5–7]. Some studies, however, fail to show signifi-
cant clinical benefit of CSII over MDI, when both ran-
domized groups received the same structured education
program [8]. CSII is more complex, requires provision of
additional training and education [9], and is a more ex-
pensive mode of therapy. A longitudinal analysis of the
Swedish National Diabetes Register found the average
costs were approximately $4000 more per annum com-
pared to MDI only [10]. However, some studies have
suggested that CSII is associated with reduced risk of
diabetes-related complications [11, 12], including lower
cardiovascular mortality [13].
Notwithstanding the benefits, there is still limited up-
take of CSII in those with type 1 diabetes, although there
have been increases, mainly in well-developed countries,
in those where CSII is reimbursed, and in younger aged
populations [1, 14]. From what is already known, the up-
take of CSII is usually lower in adults than in children
with type 1 diabetes (e.g. in Scotland [15] or Italy [16]),
due, in part, to factors such as the health system struc-
ture and different reimbursement strategies for children
and adolescents compared to adults. In Germany and
Austria, the percentage of people using CSII increased
from 1% in 1995 to 53% in 2017 across all ages, with the
highest uptake in the youngest age group (92% of
German and Austrian pre-schoolers) [14]. Comparison
between three large paediatric diabetes registries in 2015
showed that 47% of children in the United States (US -
T1D Exchange), 41% in Germany and Austria (DPV),
and 14% in the English/Welsh National Pediatric Dia-
betes Audit [17] were using CSII. Evidence from 2017
using data from large diabetes registries found the level
of uptake of CSII in adults varied from 9.4% in Scotland
[15] to 37% in Germany [14]. As CSII is fully reimbursed
in Ireland, as in most of the countries mentioned above
(excluding the US), in this study we aimed to estimate
the national and regional uptake of CSII in children, ad-
olescents and adults with type 1 diabetes in Ireland.
Methods
A retrospective cross-sectional study was conducted util-
izing the Irish Health Service Executive Primary Care
Reimbursement Service (HSE-PCRS) national pharmacy
claims database for 2011–2016. The STrengthening the
Reporting of OBservational Studies in Epidemiology
(STROBE) statement checklist was followed to ensure
the quality of conduct and reporting of the study.
Settings / data sources
The HSE-PCRS pharmacy claims database records (an-
onymously) monthly dispensed medications from the
government funded medication reimbursement schemes
in Ireland: Drug Payment (DP), General Medical Ser-
vices (GMS), and Long-Term Illness (LTI) schemes [18].
People with diabetes have their treatment-related costs
fully covered by the state (including insulin, glucometer
test strips, insulin pump infusion sets, etc.) mainly
through the LTI scheme [19]. LTI and GMS schemes
are available to all Irish citizens with diabetes, irrespect-
ive of whether their care is provided through the public
or private system or in primary or secondary care. The
database records basic demographic information, includ-
ing gender, age group and locality of residence, and the
type of medication for diabetes, according to the World
Health Organization (WHO) Anatomical Therapeutic
Classification (ATC) codes for diabetes (A10) [20]. More
detailed information about the HSE-PCRS database can
be found elsewhere [18]. Ethical approval to conduct the
study was not required as the data were anonymised and
permission was provided from the data controllers
(HSE-PCRS) for use of the data for this specific study.
Study population and definitions
The study population included people with type 1 dia-
betes living and claiming their diabetes-related prescrip-
tions, including CSII sets, in Ireland in 2016. The final
population of those with type 1 diabetes (20,081) was es-
timated as part of another study using similar method-
ology and the HSE-PCRS data-set. The criteria and
definition of a person with type 1 diabetes were complex
and included: continuous use of insulin (any type) and
glucose test strips (any type); those who used oral
hypoglycaemic agents for the 12 months prior to com-
mencing insulin, and those on long-acting insulin only,
were excluded from analysis. More details about the
methodology, its strengths and limitations, the criteria
and definitions are fully described elsewhere [19].
Statistical analysis
The uptake of CSII was calculated as the percentage of
people with type 1 diabetes claiming CSII sets in 2016.
Descriptive statistics, including percentages with 95%
confidence intervals (CIs), are presented. Type 1 diabetes
is most often described in the paediatric population, and
there are fundamental differences in the approach, treat-
ments, needs, problems and delivery of diabetes care be-
tween children and adults with type 1 diabetes [21].
Thus we decided to stratify the data for the paediatric
population (children and adolescents aged under 18
years), and adults (aged 18 and over) separately. In
addition, in a previous study on the prevalence of type 1
diabetes in Ireland the same stratification by paediatric
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and adult cases was used, as well as the stratification by
age-groups used by the Irish Central Statistics Office
[22] (0–14, 15–24, 25–34, 35–44, 45–54, 55–64, 65–74,
75+) that allowed the prevalence rates for the Irish
population to be estimated [19].
For the purposes of this study, analysis was conducted
in 18 geographical areas related to 32 Local Health Of-
fices areas [23] (Additional file 1 Table S1). Chi-square
tests (including linear test for trend for age) were used
to compare uptake of CSII across age groups and geo-
graphical regions. Significance at p < 0.05 was assumed.
The uptake by geographical regions of residence was
mapped using ArcGIS software version 10.2.2. SAS stat-
istical software version 9.4 and Microsoft Excel for Mac
2011 were used for analysis.
Results
There were 2111 people with diabetes claiming CSII sets
in 2016, providing an overall uptake of CSII of 10.5%
(95% CI: 10.1 to 10.9%; Table 1). The uptake was five-
fold higher in those aged < 18 years (34.7, 95% CI: 32.9
to 36.5%) than in those aged ≥ 18 years (6.8, 95% CI:
6.4–7.2%). No information was available on age for
n = 50 (2%). Of all those using CSII in Ireland, 43% were
children and adolescents.
The uptake of CSII varied significantly between
different age groups (Table 1) and geographical regions
(Fig. 1, Table 2). There was a significant linear associ-
ation of decreasing CSII use with increasing age (χ2 =
1678.7, p < 0.001). The highest uptake was in the youn-
gest population (38% in children aged ≤ 14 years),
through to 2.1 and 0.8% in the oldest age groups (people
aged 65–74 and over 75 years respectively; Table 1).
Significant variation in the overall uptake of CSII be-
tween regions was observed from 4% (Co. Roscommon)
to 15.8% in Co. Meath (χ2 = 213.6, p < 0.001; Table 2).
High uptake was observed in areas close to the capital
city – Dublin (12.6% in Dublin and its suburbs), in coun-
ties Kildare & Wicklow (15%) and Carlow & Kilkenny
(12.9%). There were differences in regional uptake
between the paediatric and adult populations. In the
paediatric population the uptake varied significantly
(χ2 = 105.2, p < 0.001; Fig. 1, Table 2) and was lowest in
county Mayo (12.6%), and highest in county Meath
(53.7%). The region with the lowest uptake in the paedi-
atric population was still higher than any uptake levels
in adults. In adults the uptake varied from 2% (county
Roscommon) to 9.6% (counties Kildare and Wicklow)
and the differences were significant (χ2 = 187.8,
p < 0.001; Fig. 1, Table 2). See Table 2 for more detailed
regional information.
Discussion
This study found that 10.5% of those with type 1 dia-
betes were using CSII in Ireland in 2016. Overall, the
uptake of CSII in children and adolescents was five-fold
higher than in adults. The uptake was the highest, at
38%, in the youngest age-group (0–14 years) and was
significantly lower with increasing age. There was signifi-
cant geographical heterogeneity in CSII uptake with a
four-fold variation in uptake across regions for children
and adolescents, and five-fold for adults.
In comparison to other countries where CSII therapy
is fully reimbursed (all Western European countries), the
uptake in Ireland is relatively low. The average uptake in
Nordic, Central and Western countries was 15–20% in
2010 [24]. The uptake in Ireland is even lower than in
other developed countries with no public funding, where
CSII is available mainly to those with private health in-
surance. In 2014, 12% of the population in Australia
Table 1 Uptake (n and %) of Continuous Subcutaneous Insulin Infusion (CSII) therapy in people with type 1 diabetes in Ireland in
2016
Age Group (Years) CSII therapy users (Total numbers) People with type 1 diabetes (total numbers) % Uptake of CSII 95% CI
0–14 702 1846 38.0% 35.8 to 40.2%
15–24 417 2182 19.1% 17.5 to 20.8%
25–34 239 2363 10.1% 8.9 to 11.3%
35–44 277 2831 9.8% 8.7 to 10.9%
45–54 235 2897 8.1% 7.1 to 9.1%
55–64 121 2889 4.2% 3.5 to 4.9%
65–74 55 2688 2.1% 1.5 to 2.6%
75+ 15 1948 0.8% 0.4 to 1.2%
TOTAL 2111a 20,081b 10.5% 10.1 to 10.9%
< 18 years 899 2591 34.7% 32.9 to 36.5%
≥18 years 1162 17,053 6.8% 6.4 to 7.2%
aThere were 50 missing data for age (2%) in the uptake of insulin pumps
bThere were 437 missing data for age (2%) in the prevalence of type 1 diabetes
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[25], and 59% of those with type 1 diabetes participating
in the T1D Exchange clinic registry in the US [26] were
using CSII. However, the T1D Exchange registry in-
cludes 16,061 participants from 76 diabetes US clinics
(38 adult and 38 paediatrics), so this figure may not rep-
resent that national picture as a whole.
The uptake of CSII in children and adolescents in
Ireland (34.7%) is similar to that in the UK where it was
reported as 35.7% in those aged < 18 years in England and
Wales in 2019 [27] and in the 2017 Scottish National Sur-
vey [15]. However, the uptake of CSII in these countries is
generally lower than in other Western countries. The
highest uptake of CSII in children and adolescents was ob-
served in Slovenia (74%), with Sweden and Denmark also
having > 50% uptake [28]. The study conducted within the
SWEET network for paediatric diabetes centres (based on
clinic databases from > 30 paediatric clinics) suggests an
average of 44% uptake across Europe (2016) [28], and 60%
of children and adolescents included in the US T1D Ex-
change clinic registry (38 clinics, 8483 participants aged <
18 years), [26] were using CSII in 2014.
In adults, the uptake of CSII in Ireland is also lower than
in other countries where this mode of treatment is reim-
bursed [24]. Uptake has been reported to vary from 9.4% in
Scotland [15], to 15% in England [29] and Italy [16] (data
from 2017), 21% in Denmark (in one region) [30], 22% in
Sweden (data from 2015) [10], 24% in Germany, Austria,
Switzerland and Luxemburg (data from 2017) [31]. More re-
cent data suggest that uptake of CSII in dutls from Germany
only is 37% in 2017. [14]. Data from the US suggests that
the uptake of CSII was even higher (59%) in adults in 2014
[26], but for reasons outlined above, unlike the German
data, the US figure may not be representative of the popula-
tion as a whole [14, 26]. Uptake of CSII in Irish adults is
similar to Wales (6.7%) [29], and to findings of the national
audit of CSII care in the UK conducted in 2012 [9]. The au-
thors of the UK report concluded that this prevalence was
“well below the expectations of the National Institute for
Health and Clinical Excellence (NICE) guidelines (15-20%)
or the European average (15%)” and, therefore, steps have
been undertaken in the UK, in particular in England, to im-
prove the uptake [15, 29, 32]. As a result, uptake in adults
Fig. 1 The maps of the uptake of Continuous Subcutaneous Insulin Infusion in children and adolescents and adults with type 1 diabetes in
Ireland in 2016. Copyright: Katarzyna Anna Gajewska
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in England and Scotland has doubled since 2012 [15, 29],
but this is still below that in the Nordic countries, Germany
or the US [10, 26, 30, 31]. In Ireland, there are no standard-
ized criteria or clinical recommendations for the use of CSII
therapy in adults at present [33], which may be one of the
factors for the low uptake of CSII. Commencement of CSII
is usually at the discretion of the physician and team
looking after the person with diabetes although aiming to
optimize control, limit hypoglycaemia, improve
hypoglycaemia awareness and personal preferences would
be common indications. Having more firm guidelines could
direct physicians to recommend CSII more often. On the
other hand, bearing in mind lower uptake in the UK when
comparing to Nordic countries, strict criteria, as those in
the NICE guidelines, may have an impact on the poor up-
take of CSII also. It is worth to note, that many health-care
professionals in Ireland receive their postgraduate training
(as well as training to provide CSII services) in the UK,
therefore the NICE criteria are well-known by significant
percentage of specialists in diabetes in Ireland. Other pos-
sible barriers to uptake, in particular in adults, might be
similar to those explored by Italian researchers. According
to the Third Italian Survey of CSII, high costs of CSII and
lack of multidisciplinary teams (MDT) are perceived as lim-
iting factors for CSII uptake [34]. The availability of CSII
was explored more in-depth in a national survey of CSII
services provision in adult clinics in Ireland. The scarcity of
trained staff, as shown in the survey findings, means that
full MDTs were not always available (e.g. lack of dietetic
support), and the lack of MDT and perceived work over-
load were listed as barriers to CSII provision [35]. Another
barrier might be related to people with diabetes lack of will-
ingness to be attached to a device and a burden associated
with technology use [36, 37].
The diversity in uptake of CSII between different age
groups is common. Authors of the study conducted in
Sweden concluded that people aged between 20 and 30
years were more than twice as likely to initiate use of
CSII than those aged 40–50 years [38], and data from
registries suggest that younger people with type 1 dia-
betes use CSII more often than older adults [15, 29].
CSII is recommended by ISPAD as a preferred mode of
treatment in the youngest population [1]. CSII is often
initiated in pre-school children due to their and their
families’ needs related to unpredictable food patterns,
low insulin requirements, reduction in the number of in-
jections, ease of insulin delivery and needle-phobia [1],
which helps explain why CSII is used more by younger
people [29]. These needs have been recognized by the
Irish National Paediatric Clinical Programme which
introduced a model of care for the provision of CSII in
children aged ≤5 years in 2012 [39]. This policy
Table 2 Geographical differences in the uptake of continuous subcutaneous insulin infusion in a whole population, children and
adolescents, and adults over 18 with type 1 diabetes in Ireland in 2016
Geographical area Uptake of CSII – All (%); (95% CI) Uptake (%) of CSII in children and adolescents Uptake (%) of CSII in adults
Carlow Kilkenny 12.89% (10.30–15.44%) 39.36% (29.49–49.24%) 8.64% (6.33–10.95%)
Clare 4.93% (2.82–7.03%) 24.32% (10.50–38.15%) 3.01% (1.26–4.77%)
Cork Combined 7.60% (6.53–8.67%) 31.64% (26.14–37.13%) 4.43% (3.55–5.32%)
Donegal 9.59% (7.66–11.51%) 42.86% (34.66–51.05%) 3.49% (2.17–4.81%)
Dublin Combined 12.59% (11.72–14.36%) 38.68% (34.80–42.56%) 9.21% (8.39–10.03%)
Galway 10.69% (8.70–12.68%) 28.70% (20.43–36.96%) 7.95% (6.08–9.82%)
Kerry 4.31% (2.75–5.88%) 20.29% (10.80–29.78%) 2.43% (1.17–3.69%)
Kildare and Wicklow 15.03% (13.28–16.78%) 44.00% (37.85–50.15%) 9.63% (8.03–11.24%)
Laois and Offaly 10.72% (8.29–13.15%) 30.53% (21.27–39.79%) 7.03% (4.85–9.22%)
Limerick and Tipperary 7.75% (6.38–9.12%) 29.25% (23.12–35.37%) 4.03% (2.93–5.14%)
Longford Westmeath 9.67% (7.12–12.22%) 27.50% (17.72–37.28%) 6.56% (4.21–8.91%)
Louth 11.77% (9.33–14.21%) 38.78% (29.13–48.42%) 7.09% (4.97–9.21%)
Mayo 6.86% (4.70–9.02%) 12.64% (5.66–19.63%) 5.50% (3.36–7.65%)
Meath 15.76% (13.21–18.30%) 53.66% (44.85–62.47%) 8.79% (6.63–10.95%)
Roscommon 4.00% (1.44–6.56%) 18.52% (3.87–33.17%) 2.03% (0.06–4.00%)
Sligo, Leitrim, Cavan, Monaghan 8.55% (6.80–10.30%) 30.58% (22.37–39.79%) 5.32% (3.81–6.83%)
Waterford City and County 8.15% (5.73–10.57%) 20.45% (12.03–28.88%) 5.33% (3.11–7.55%)
Wexford 9.55% (7.42–11.68%) 36.00% (25.14–46.86%) 6.31% (4.42–8.20%)
ALL IRELAND 10.51% (10.09–10.94%) 34.70% (32.86–36.53%) 6.81% (6.44–7.19%)
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document recommends offering CSII to every child with
type 1 diabetes under the age of 5 years, which may have
contributed to the large difference in uptake between
paediatric and adult populations.
Evidence on geographical variation in CSII uptake [15,
27, 29, 40] is lacking. Where evidence is available, for ex-
ample, in Scotland, the variation was found to be two-fold
from 27.1 to 60% in the paediatric population and 6.7 to
15.2% in adults [15] in 2017. This variation was not as high
as that found in our study. There were four-fold differences
between the overall uptake in Ireland and in children in ad-
olescents, while a five-fold difference was observed in
adults. Overall, the areas of high uptake seem to be central-
ized around Dublin both in the paediatric and adult popula-
tions. Low uptake seems to be more often in rural areas,
such as Roscommon, Clare or Kerry. The rural-urban dif-
ference might partly explain such a heterogeneity, although
there are exceptions such as Donegal which has one of the
highest uptakes of CSII in children and adolescents despite
being considered “rural”. Another explanation might be re-
lated to the age distribution of local populations. The youn-
gest populations are in parts of Dublin and adjacent
counties, whereas the oldest are in rural counties [41].
However some areas with older populations also have
higher uptake than areas where the population is younger.
This suggests that determinants are more complex than
age, and rural-urban disparities. Previous data from Italy
also shows geographical disparity even though the Italian
health system covers the cost of devices; geographical dis-
parity was explained by different regional regulations in
terms of prescription rules and requirements [34]. In
Ireland, prescription regulations are the same, but diversity
in uptake could be affected by local health offices where de-
cisions regarding funding are made [42].
This study aimed to estimate the uptake of CSII in
Ireland and concludes that it is low both in the paediat-
ric and adult populations. The reasons for such low up-
take are not related to reimbursement since CSII is fully
reimbursed in Ireland. The reasons are more complex,
and may include lack of national standardized docu-
ments including guidelines for commencing CSII, the
perceived excessive workload and the lack of resources
[16, 34] This, however, has to be explored further with a
use of more complex research methods.
The main strength of this study is that it is population-
based, nationwide and based on objective data. Our re-
gional findings relate to the residence of those with diabetes
and not where they receive their diabetes care; thus the
findings accurately describe local access to CSII. This is the
first study describing the uptake of CSII in all regions and
the entire population of people with type 1 diabetes in
Ireland. Data based on prescriptions claimed for CSII sets
are a reliable and accurate source of information regarding
CSII utilization.
This study has some limitations. It was not possible to
monitor discontinuation of CSII, where others have shown
discontinuation rates in the range 1–4% [43]. Although
the numbers using CSII reported are accurate, the uptake
rates may be impacted on by the definition of type 1 dia-
betes cases, which was based on diabetes-specific prescrip-
tions included in the pharmacy claims database. As
information on the diagnosis (i.e. ICD-10 codes) is not
available in the HSE-PCRS database and there is no dia-
betes registry in Ireland, some cases of people with type 2
diabetes receiving basal-bolus therapy or CSII may have
been misclassified as type 1 diabetes. In addition, as the
HSE-PCRS database is mainly used for the administrative
purpose and does not contain any other medical informa-
tion, there was no possibility to monitor the outcomes of
CSII use, i.e. in levels of glycated haemoglobin (HbA1c).
Moreover, because Continuous Glucose Monitoring
(CGM) sensors are not included in the HSE-PCRS data-
base (funding is covered from a different budget), we were
unable to investigate the uptake of sensor-augmented in-
sulin pump therapy use.
Conclusions
Uptake of CSII remains low in Ireland when compared to
other countries where, like Ireland, CSII is fully reimbursed.
The uptake is five-fold higher in children/adolescents than
in adults. Our regional findings accurately describe local ac-
cess to CSII and suggest this access is unequal. This study
highlights the potential under-utilisation of CSII in Ireland
and suggests that further studies exploring potential bar-
riers, both from the health-care providers’ and patients’ per-
spectives, are warranted. An understanding of the reasons
for the low uptake of CSII will have important implications
for improving the quality of care for people living with type
1 diabetes in Ireland. These findings will help to inform
health service users and policymakers, and can help to sup-
port health-service planners in making decisions on health-
service resource distribution. Also, our study suggests that
in a country without a national diabetes register, routinely
collected administrative pharmacy claims data can be uti-
lized to estimate the uptake of CSII. Finally, this study adds
to limited international evidence on the uptake of CSII
therapy in those with type 1 diabetes.
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